Phase II trial of intravesical camrelizumab in BCG-unresponsive high-risk non-muscle invasive bladder cancer

被引：0
|
作者：
Shen, Yijun
Peng, Liangju
Xu, Peihang
Wang, Yanhao
Wang, Xiang
Yao Xudong
Liu, Yushan
Ye, Ding-Wei
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[2] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Sch Med, Shanghai, Peoples R China
[3] Tongji Univ, Shanghai Tenth Peoples Hosp, Shanghai, Peoples R China
[4] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4594
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A phase 1/2 study of EG-70 (detalimogene voraplasmid) intravesical monotherapy for patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ
    Bryce, Richard
    Tosone, Christine
    Sullivan, James C.
    Linback, Tammy
    Steinberg, Gary D.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [42] Clinical trial of high dose hyperthermic intravesical mitomycin C for intermediate and high-risk non-muscle invasive bladder cancer during BCG shortage
    Grimberg, Dominic C.
    Dudinec, John
    Shah, Ankeet
    Inman, Brant A.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2021, 39 (08) : 498.e13 - 498.e20
  • [43] BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG
    Ashish M. Kamat
    Marc Colombel
    Debasish Sundi
    Donald Lamm
    Andreas Boehle
    Maurizio Brausi
    Roger Buckley
    Raj Persad
    Joan Palou
    Mark Soloway
    J. Alfred Witjes
    Nature Reviews Urology, 2017, 14 : 244 - 255
  • [44] A phase I/II study of EG-70 (detalimogene voraplasmid) intravesical monotherapy for patients (pts) with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS)
    Palou, J.
    Marcq, G.
    Steinberg, G.
    Toscone, C.
    Sullivan, J.
    Linback, T.
    Pruthi, R.
    Bryce, R.
    Brown, G.
    ANNALS OF ONCOLOGY, 2024, 35 : S1165 - S1165
  • [45] Association Between Antibiotic Treatment and the Efficacy of Intravesical BCG Therapy in Patients With High-Risk Non-Muscle Invasive Bladder Cancer
    Pak, Sahyun
    Kim, Sun-Young
    Kim, Sung Han
    Joung, Jae Young
    Park, Weon Seo
    Chung, Jinsoo
    Lee, Kang Hyun
    Seo, Ho Kyung
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [46] A PHASE 1 TRIAL OF INTRAVESICAL CABAZITAXEL, GEMCITABINE, AND CISPLATIN (CGC) FOR THE TREATMENT OF NON-MUSCLE INVASIVE BCG UNRESPONSIVE UROTHELIAL CARCINOMA OF THE BLADDER
    DeCastro, G. Joel
    Anderson, Christopher
    Kates, Max
    Buckley-Matura, Bridget
    Sui, Wilson
    Lee, Shing M.
    Holder, Dara
    Virk, Renu
    Drake, Charles
    Abate-Shen, Cory
    McKiernan, James
    JOURNAL OF UROLOGY, 2019, 201 (04): : E623 - E623
  • [47] ONCOLOGIC OUTCOMES OF GEMCITABINE-DOCETAXEL COMBINATION INTRAVESICAL BLADDER SPARING THERAPY COMPARED TO UPFRONT RADICAL CYSTECTOMY IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER
    Drupad, Annapureddy
    Jacob, Taylor
    Jeffrey, Howard
    Solomon, Woldu L.
    Yair, Lotan
    Shen, Tan Wei
    Ashish, Kamat
    Ian M, McElree
    Vignesh, Packiam T.
    Michael, O'Donnell
    Davaro, Facundo
    Roger, Li
    Kendrick, Yim
    Mark, Preston A.
    Stephen, Harrington
    Elizabeth, Dyer
    Jay, Raman
    Anna, Black
    Peter, Black
    Pratik, Kanabur
    Seth, Lerner
    Mathieu, Roumiguie
    Gary, Steinberg
    William, Huang
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2024, 42 : S52 - S53
  • [48] Race, ethnicity, and gender reporting in North American clinical trials for BCG-unresponsive non-muscle invasive bladder cancer
    Fletcher, Sean A.
    Bivalacqua, Trinity J.
    Brawley, Otis W.
    Kates, Max
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2022, 40 (05) : 195.e13 - 195.e18
  • [49] BCG unresponsive non-muscle invasive bladder cancer: The beginning of a new era?
    Guerrero-Ramos, F.
    ACTAS UROLOGICAS ESPANOLAS, 2023, 47 (06): : 329 - 331
  • [50] S1605: Phase II trial of atezolizumab in BCG-unresponsive nonmuscle invasive bladder cancer.
    Black, Peter C.
    Catherine, Tangen
    Lerner, Seth P.
    McConkey, David James
    Lucia, M. Scott
    Woods, Michael
    Bivalacqua, Trinity
    Kassouf, Wassim
    Bangs, Richard Carlton
    Plets, Melissa
    Thompson, Ian Murchie
    Singh, Parminder
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
12345